New Hope, PA – RG+A, Inc., a leading healthcare consulting and marketing research firm, announced today that business professional Carol S. Mann has agreed to serve as Chief Executive Officer and pharmaceutical leader Dr. Martin Jernigan has joined the company as President and Chief Operating Officer, effective immediately. They will join Chairman and Founder Roger Green to create a three-person executive leadership team for the company.
Ms. Mann has served as interim CEO since April 2018. During that time, she has overseen a 40% reduction in G & A costs and led a restructuring of the company’s finances. As permanent CEO, she will continue to focus on the overall long-term strategic direction and success of the company. Dr. Jernigan, who joined RG+A last month, will lead the company’s research, consulting and sales activities while working directly with some key clients. The third member of the team, Mr. Green, will focus primarily on working with clients and key stakeholders to assure that RG+A’s products and services keep evolving to meet the needs of a rapidly-changing industry.
“In assuming these critical roles, Carol and Martin provide the talent and leadership necessary to write a successful next chapter in the RG+A story,” said Roger Green, Chairman and Founder of RG+A. “Their commitment will empower us to achieve ambitious objectives in improving corporate profitability while creating exciting new products and services that our clients need.”
Newly Appointed CEO
Carol Mann is an award-winning chief executive with accomplishments with high growth companies in a variety of industries. Her leadership experience began over 30 years ago, she was known as a pioneer of the “turn-around” industry, often serving as interim CEO. Carol helped form the restructuring divisions at KPMG and at BDO Seidman LLP, two of the most prominent “Big 5” accounting and business consulting firms in the world. As a sought-after speaker and panelist, she has contributed to business textbooks, articles in Fortune Magazine, and US News & World Report and was also featured in Enterprising Women: Lessons from the 100 of the Greatest Entrepreneurs of Our Day. In 2005, Mann was honored with the Women of Distinction Award, as well as Congressional and Senatorial Commendations for her work. Carol attended Philadelphia University where she studied Business Administration.
“I am thrilled to be a part of the RG+A team”, said Carol Mann. “Business growth requires inspiration and execution, and there are ample amounts of inspiration to pull from the RG+A team!”
Jernigan named President and COO
Dr. Jernigan brings over 20 years of strategic pharmaceutical leadership experience in U.S. and Global commercial roles to RG+A. Most recently, he spent 12 years at Novo Nordisk where he oversaw the U.S. pre-launch and launch of Victoza® (liraglutide) and went on to serve as Vice President, first for its GLP-1 franchise growing it to a $2B franchise and later for its $3B insulin business. Earlier in his career, he worked in commercial, business development, strategy and marketing roles of increasing responsibility at Johnson & Johnson, Aventis, Hoechst Marion Roussel and Marion Merrell Dow. Dr. Jernigan received his Pharmacy degree from Auburn University and a Master of Science and Ph.D. in Health Care Administration with a concentration in Pharmaceutical Marketing from the University of Mississippi. He currently teaches Pharmaceutical Marketing at Rutgers MBA global business management program.
“I am excited to join RG+A where I can bring my experience from my pharmaceutical career to help clients and my colleagues impact more patients and customers across many pharmaceutical, biotech and other healthcare related companies,” said Dr. Jernigan. I thrive at the intersection of business and science and I look forward to bringing this passion to growing our business where we can contribute to our clients’ commercial success.”
RG+A is a consulting and marketing research firm based in New Hope, PA. With over 25 years of proven experience applying unique and creative methods to solve complex problems, RG+A has earned a reputation as an innovator in primary research and consulting for the healthcare industry, advising pharmaceutical, biotechnology, and medical device companies on commercial evaluations, business development, pre-launch planning, forecasting, pricing, market valuations, and strategy development.
For more information, connect on LinkedIn:
Media Contacts for RG+A:
Martin Jernigan, 267.744.6410, email@example.com
Rachel Carver, 267.744.6411, firstname.lastname@example.org